Dr Levis on Gilteritinib in RelapsedRefractory FLT3Mutated AML

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=A9uP0H80goo

Mark James Levis, MD, PhD, program leader of Hematologic Malignancies and Bone Marrow Transplant Program at Sidney Kimmel Comprehensive Cancer Center, and professor of oncology, Johns Hopkins Medicine, discusses an analysis of gilteritinib (Xospata) in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML) harboring other common co-mutations or a high FLT3-internal tandem duplication (ITD) allelic ratio. • Website: https://www.onclive.com • Twitter: / onclive • Facebook: / onclive • LinkedIn: / onclive

#############################

New on site